References
- CaA Cancer Journal for Clinicians. Cancer Statistics 1983. American Cancer Society, New York 1983; 33: 1
- Posner J B. Neurological complications of systemic cancer. Med Clin North Am 1971; 44: 625–646
- Tagnon J H, Hildebrand J. Paraneoplastic syndromes. Exp J Cancer Clin Oncol 1981; 17: 969–990
- Denny-Brown D. Primary sensory neuropathy with muscular changes associated with carcinoma. J Neurol Neurosurg Psychiatr 1948; 11: 73–87
- Kinsbourne M. Myoclonic encephalopathy of infants. J Neurol Neurosurg Psychiatr 1962; 25: 271–280
- Henson R A, Hoffman H L, Urich M. Encephalomyelitis with carcinoma. Brain 1964; 88: 443–464
- Engel A G. Myasthenia gravis and myasthenic syndromes. Ann Neurol 1984; 16: 519–534
- Aranson B GW. Paraneoplastic syndromes of muscle, nerve, and brain. Immunological Considerations in Clinical Neuroimmunology, F C Rose. Blackwell, Oxford 1979
- Lang B, Newsom-Davis J, Wray D, et al. Autoimmune etiology for myasthenia (Eaton-Lambert) syndrome. Lancet 1981; II: 224–226
- Lambert E H, Elmquist D. Quantal components of end plate potentials in the myasthenic syndrome. Ann NY Acad Sci 1971; 183: 183–199
- Fukuga H, Engel A G, Lang B, et al. Passive transfer of Lambert-Eaton myasthenia syndrome with IgG from man to mouse depletes the presynaptic active zones. Proc Nat Acad Sci (USA) 1983; 80: 7636–7660
- Roberts A, Perera S, Lang B, et al. Paraneoplastic myasthenic syndrome IgG inhibits 45 CA 2+ flux in a human small cell carcinoma line. Nature 1985; 317: 737–739
- Patchell R A, Posner J B. Neurological complications of systemic cancer. Neurol Clin 1985; 3(4)729–750
- Layser R. Neuromuscular manifestation of systemic disease. Contemp Neurol Series 1984; 25: 264–282
- Jaeckle K A, Graus F, Naughton A, et al. Autoimmune response of patients with paraneoplastic cerebellar degeneration to a Purkinje cell cytoplasmic protein antigen. Ann Neurol 1985; 18: 592–600